The aim of the current nationwide, multicentre Austrian study was to investigate systematically the intravenous administration of pantoprazole. The study objectives were to collect and evaluate ...

"Topical administration in its current form is inferior to intravenous TxA and should not be used." The trial, called DEPOSITION, intended to enroll 3,800 patients but stopped after enrolling ...

A California company offering the world's first injectable CBD product is in hot water after the FDA said the IV injections ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Disruptions from Hurricane Helene exacerbated shortages of critical intravenous fluids in the United States, and now the ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Finally, the rates of absorption and time to peak plasma concentrations are comparable to IV administration, and are generally superior to subcutaneous or intramuscular routes. The use of IN ...

is offering an Immunization and Injection Administration Refresher Program (IIARP). The IIARP has been developed to address the current need for pharmacist recertification. During the IIARP course, ...